Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Relmada Therapeutics to post earnings of ($0.90) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last issued its quarterly earnings data on Tuesday, March 19th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.04. On average, analysts expect Relmada Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Relmada Therapeutics Stock Down 0.8 %
Relmada Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $3.82. 65,817 shares of the company's stock were exchanged, compared to its average volume of 235,637. The firm has a market capitalization of $115.25 million, a P/E ratio of -1.16 and a beta of 0.27. Relmada Therapeutics has a fifty-two week low of $2.36 and a fifty-two week high of $7.22. The company's 50 day simple moving average is $4.86 and its 200-day simple moving average is $4.01.
Relmada Therapeutics Company Profile
(
Get Free Report)
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
Before you consider Relmada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.
While Relmada Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
